Condition: Acute Lymphocytic Leukemia · Lymphoma,Non-Hodgkin · Relapsed Refractory Multiple Myeloma · Sponsor: Shanxi Bethune Hospital
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
This description comes directly from the study's public registry record.
JIA WEI · CHN13986102084 · ngc2237fh@163.com
Always discuss trial participation with your own doctor first.
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06783816